An engineered IgM antibody targeting CD20 has enhanced complement-dependent cytotoxicity compared with an IgG
- 14 September 2025
- journal article
- research article
- Published by Elsevier in Experimental Hematology
- Vol. 152, 105250
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Quantification of drug-induced fractional killing using high-throughput microscopySTAR Protocols, 2021
- Kinetic Heterogeneity of Cancer Cell Fractional KillingCell Reports, 2020
- Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9Clinical Immunology, 2017
- Molecular Basis of Assembly and Activation of Complement Component C1 in Complex with Immunoglobulin G1 and AntigenMolecular Cell, 2016
- Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cellsMolecular Immunology, 2016
- Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignanciesCancer Treatment Reviews, 2013
- The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopeniasAutoimmunity Reviews, 2007
- Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell linesLeukemia Research, 2006
- Role of natural and immune IgM antibodies in immune responsesMolecular Immunology, 2000
- IgM - molecular requirements for its assembly and functionImmunology Today, 1989